Effect of telmisartan in limiting the cardiotoxic effect of daunorubicin in rats

Journal of Pharmacy and Pharmacology

Volumn 62, Issue 12, 2010, Pages 1776-1783

  Arozal, Wawaimuli ^a,b   Watanabe, Kenichi ^a   Veeraveedu, Punniyakoti T ^a   Thandavarayan, Rajarajan A ^a   Harima, Meilei ^a   Sukumaran, Vijayakumar ^a   Suzuki, Kenji ^c   Kodama, Makoto ^c   Aizawa, Yoshifusa ^c  

^a NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

^b UNIVERSITY OF INDONESIA   (Indonesia)

^c NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Angiotensin II; Cardiotoxicity; Daunorubicin; Oxidative stress; Telmisartan

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ANGIOTENSIN 1 RECEPTOR; DAUNORUBICIN; GELATINASE A; GLUTATHIONE PEROXIDASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MALONALDEHYDE; PROTEIN P22; PROTEIN P47; PROTEIN P67; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; TELMISARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVITY; HEART FUNCTION; HEART PROTECTION; HEMODYNAMICS; MALE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BENZIMIDAZOLES; BENZOATES; DAUNORUBICIN; DOXORUBICIN; HEART; HEART DISEASES; MALE; MALONDIALDEHYDE; MATRIX METALLOPROTEINASE 2; MYOCARDIUM; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ANGIOTENSIN; VENTRICULAR FUNCTION, LEFT;

EID: 78149394964     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2010.01196.x     Document Type: Article

References (54)

1. Minotti G et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56: 185-229.
2. Buzdar AU et al. Early and delayed clinical cardiotoxicity of doxorubicin. Cancer 1985; 55: 2761-2765.
3. Gottdiener JS et al. Doxorubicin cardiotoxicity: assessment of late left ventricular dysfunction by radionuclide cineangiography. Ann Intern Med 1981; 94: 430-435.
4. Fukazawa R et al. Early detection of anthracycline cardiotoxicity in children with acute leukemia using exercise-based echocardiography and Doppler echocardiography. Jpn Circ J 1994; 58: 625-634.
5. Iarussi D et al. Anthracyline-induced cardiotoxicity in children with cancer: strategies for prevention and management. Paediatr Drugs 2005; 7: 67-76.
6. Siehl JM et al. Ifosfamide/liposomal daunorubicin is a well tolerated and active first-line chemotherapy regimen in advanced soft tissue sarcoma: results of a phase II study. Cancer 2005; 104: 611-617.
7. Teixeira RS et al. Delivery of daunorubicin to cancer cells with decreased toxicity by association with a lipidic nanoemulsion that binds to LDL receptors. J Pharm Pharmacol 2008; 60: 1287-1295.
8. Simunek T et al. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 2009; 61: 154-171.
9. Gianni L et al. Anthracyline cardiotoxicity: from bench to bedside. J Clin Oncol 2008; 26: 3777-3784.
10. Sawyer DB et al. Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. Circ Res 1999; 84: 257-265.
11. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007; 292: C82-C97.
12. Singh VP et al. Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes 2008; 57: 3297-3306.
13. Toko H et al. Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy. Hypertens Res 2002; 25: 597-603.
14. Ibrahim MA et al. Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity. Pharmacol Res 2009; 60: 378-381.
15. Soga M et al. Effects of angiotensin II receptor blocker (candesartan) in daunorubicin-induced cardiomyopathic rats. Int J Cardiol 2005; 110: 378-385.
16. Nakamae H et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer 2005; 104: 2492-2498.
17. Yamagishi S, Takeuchi M. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Med Hypotheses 2005; 64: 476-478.
18. Kobayashi N et al. Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats. Am J Hypertens 2008; 2: 576-581.
19. Cianchetti S et al. Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells. Atherosclerosis 2008; 198: 22-28.
20. Pouna P et al. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention. Br J Pharmacol 1996; 117: 1593-1599.
21. Qin F et al. Inhibition of NADPH oxidase reduces myocardial oxidative stress and apoptosis and improves cardiac function in heart failure after myocardial infarction. Free Radic Biol Med 2007; 43: 271-281.
22. Gurusamy N et al. Dominant negative 14-3-3 promotes cardiomyocytes apoptosis in early stage of type I diabetes mellitus through activation of JNK. Biochem Biophys Res Commun 2004; 320: 773-780.
23. Smith PK et al. Measurement of protein using bicinchoinic acid. Anal Biochem 1985; 150: 76-85.
24. Elbl L et al. The late consequences of anthracycline treatment on the left ventricular function after treatment for childhood cancer. Eur J Pediatr 2003; 162: 690-696.
25. Germanakis I et al. Troponins and natriuretic peptides in the monitoring of anthracycline cardiotoxicity. Pediatr Blood Cancer 2008; 51: 327-333.
26. Ito H et al. Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. Proc Natl Acad Sci USA 1990; 87: 4275-4279.
27. Li L et al. Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy. Circulation 2006; 113: 535-543.
28. Cardinale D et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006; 114: 2427-2481.
29. Chow AK et al. Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature. Br J Pharmacol 2007; 152: 189-205.
30. Aupperle H et al. Effects of autologous stem cells on immunohistochemical patterns and gene expression of metalloproteinase and their tissue inhibitors in doxorubicin cardiomyopathy in a rabbit model. Vet Pathol 2007; 44: 494-503.
31. Kizaki K et al. Enhanced gene expression of myocardial matrix metalloproteinases 2 and 9 after acute treatment with doxorubicin in mice. Pharmacol Res 2006; 53: 341-346.
32. Rutschow S et al. Myocardial proteases and matrix remodeling in inflammatory heart disease. Cardiovasc Res 2006; 69: 646-656.
33. De Nigris F et al. Prominent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heart. Eur J Cancer 2008; 44: 334-340.
34. Minotti G. NADPH and adriamycin-dependent microsomal release of iron and lipid peroxidation. Arch Biochem Biophys 1990; 277: 268-276.
35. Guzi J et al. Effect of quarcetin on daunorubicin-induced heart mitochondria changes in rats. Physiol Res 2003; 52: 773-780.
36. Injac R et al. Acute doxorubicin nephrotoxicity in rats with malignant neoplasma can be successfully treated with fullerenol C60(OH)24 via suppression of oxidative stress. Pharmacol Rep 2008; 60: 742-749.
37. Iqbal M et al. Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats. Pharmacol Rep 2008; 60: 382-390.
38. Dziegiel P et al. Role of exogenous melatonin in reducing the cardiotoxic effect of daunorubicin and doxorubicin in the rat. Exp Toxicol Pathol 2002; 53: 433-439.
39. Hoda E et al. Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4. J Pharm Pharmacol 2004; 56: 757-768.
40. Sterba M et al. Cardioprotective effects of a novel iron chelator, pyridoxal 2-chlorobenzoyl hydrazone, in the rabbit model of daunorubicin-induced cardiotoxicity. J Pharmacol Exp Ther 2006; 319: 1336-1347.
41. Harrison DG et al. Interactions of angiotensin II with NAD(P)H oxidase, oxidative stress and cardiovascular disease. J Renin Angiotensin Aldosterone Syst 2003; 4: 51-61.
42. Dhalla SN et al. Role of oxidative stress in cardiovascular diseases. J Hypertens 2000; 18: 655-673.
43. Kitayakara C et al. Salt intake, oxidative stress and renal expression of NADPH oxidase and superoxide dismutase. J Am Soc Nephrol 2003; 14: 2775-2782.
44. Griendling KK et al. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000; 86: 494-501.
45. Tonissen KF, Di Trapani G. Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy. Mol Nutr Food Res 2009; 53: 87-103.
46. Ravi D et al. Endogeous thioredoxin is required for redox cycling of anthracyclines and p53-dependent apoptosis in cancer cells. J Biol Chem 2005; 280: 40084-40096.
47. Wong YT et al. Elevation of oxidative-damage biomarkers during aging in F2 hybrid mice: protection by chronic oral intake of resveratrol. Free Radic Biol Med 2009; 46: 799-809.
48. Hellin AC et al. Nuclear factor-kappaB dependent regulation of p53 gene expression induced by daunomycin genotoxic drug. Oncogene 1998; 16: 1187-1195.
49. Boland MP et al. Daunorubicin activates NFkappaB and induces kappaB-dependent gene expression in HL-60 promyelocytic and Jurkat T lymphoma cells. J Biol Chem 1997; 272: 12952-12960.
50. Pan Q et al. Angiotensin II stimulates MCP-1 production in rat glomerular endothelial cells via NAD(P)H oxidase-dependent nuclear factor-kappa B signaling. Braz J Med Biol Res 2009; 42: 531-536.
51. Qin XJ et al. Protection of multiple antioxidants Chinese herbal medicine on the oxidative stress induced by adriamycin chemotherapy. J Appl Toxicol 2008; 28: 271-282.
52. Chen QM, Tu VC. Apoptosis and heart failure: mechanism and therapeutic implications. Am J Cardiovasc Drugs 2002; 2: 43-57.
53. Sharov VG et al. Hypoxia, angiotensin II, and norepinephrine mediated apoptosis is stimulus specific in canine failed cardiomyocytes: a role for p38 MAPK, Fas-L and cyclin D1. Eur J Heart Fail 2003; 5: 121-129.
54. 2+ calmodulin protein kinase II and promotes a death pathway conserved across different species. Circ Res 2009; 105: 1204-1212.